Biovest International, Inc. Release: New Phase III Data Analysis for BiovaxID(R), Personalized Lymphoma Vaccine, to Be Presented at American Society of Hematology Annual Meeting

TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: BVTI) today announced that BiovaxID®, Biovest’s personalized lymphoma vaccine, will be featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Monday, December 6th in Orlando, Florida.